ReviewClinical immunology (Orlando, Fla.)2012
IL-2 controls trafficking receptor gene expression and Th2 response for skin and lung inflammation.
Review in Clinical immunology (Orlando, Fla.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Serial Expression of Pro-Inflammatory Biomarkers in Acute Lung Injury During the Post-Resuscitation Periods in Rats with Cardiac Arrest.International journal of molecular sciences · 2026Article
- Article
- Association of serum interleukin-2 with severity and prognosis in hospitalized patients with community-acquired pneumonia: a prospective cohort study.Internal and emergency medicine · 2024Article
- A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis.The Prostate · 2023Article
- Article
- Do inflammasome impact COVID-19 severity?Virusdisease · 2021Review
- Targeting Regulatory T Cells for Therapy of Lupus Nephritis.Frontiers in pharmacology · 2021Review
- Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity.Mediators of inflammation · 2020Article
- IL233, A Novel IL-2 and IL-33 Hybrid Cytokine, Ameliorates Renal Injury.Journal of the American Society of Nephrology : JASN · 2017Article
- Regulatory T Cells Suppress Inflammation and Blistering in Pemphigoid Diseases.Frontiers in immunology · 2017Article
- Impact of pulmonary exposure to gold core silver nanoparticles of different size and capping agents on cardiovascular injury.Particle and fibre toxicology · 2016Article
- B cells are critical for autoimmune pathology in Scurfy mice.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Both Il2(-/-) mice and Scurfy (Sf) mutant mice that are deficient in FoxP3, develop multi-organ inflammation but only the latter display severe skin and lung inflammation. In contrast, Sf.Il2(-/-) double mutant mice do not display skin inflammation and markedly reduced lung inflammation. In this review, we summarize our recent findings based on microarray, q-PCR and functional studies of 10 Sf double mutant mice. These studies revealed novel pro-inflammatory functions of IL-2 in regulating inflammation in an organ-specific manner. IL-2 exerts its "organ-specific" pro-inflammatory function by regulating the migration and retention of CD4(+) T-cells (both Th1 and Th2) specifically to the skin and lung. In addition, IL-2 is also required for regulating the Th2 cytokine response during T-cell activation. Further studies on these IL-2-regulated genes will help in identifying novel targets for intervention in inflammatory diseases of skin and lung.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.